← Leaderboards
Michael Copenhaver
University Of Connecticut Storrs
$14,825,422
Attributed
$14,825,422
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,825,422 · 8
By mechanism
R01$11,972,018 · 4
K24$1,143,247 · 1
K02$697,150 · 1
K23$618,595 · 1
R21$394,412 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Connecticut Storrs
Same institution · by research overlap
- Seth C Kalichman$47,348,886
- Jeffrey D Fisher$15,835,677
- Deborah A Shelton$1,091,574
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsRisk BehaviorsAids PreventionProgramsPharmaceutical PreparationsBehavior TherapyEvidence BaseFundingRisk ReductionHiv RiskDesignUnited States National Institutes Of HealthCommunitiesScienceTreatment ProgramEvidence Based InterventionCenters For Disease Control And Prevention (U.S.)PersonsResearch PersonnelPrevention ApproachSkillsBehavioralAids/Hiv ProblemResponse
Grant awards (37)
Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP$899,561
R01 · FY2025 · DA · contact PI
Optimizing HIV Prevention Among High-Risk Opioid-Dependent Persons$195,507
K24 · FY2025 · DA · contact PI
Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP$916,114
R01 · FY2024 · DA · contact PI
Optimizing HIV Prevention Among Opioid-Dependent Persons$189,548
K24 · FY2024 · DA · contact PI
Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP$569,423
R01 · FY2023 · DA · contact PI
Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP$395,345
R01 · FY2023 · DA · contact PI
Optimizing HIV Prevention Among Opioid-Dependent Persons$189,548
K24 · FY2023 · DA · contact PI
Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP$605,594
R01 · FY2022 · DA · contact PI
Optimizing HIV Prevention Among Opioid-Dependent Persons$189,548
K24 · FY2022 · DA · contact PI
Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs$590,105
R01 · FY2021 · DA · contact PI
Optimizing HIV Prevention Among Opioid-Dependent Persons$189,548
K24 · FY2021 · DA · contact PI
Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs$619,760
R01 · FY2020 · DA · contact PI
Optimizing HIV Prevention Among Opioid-Dependent Persons$189,548
K24 · FY2020 · DA · contact PI
Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs$632,106
R01 · FY2019 · DA · contact PI
Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs$632,653
R01 · FY2018 · DA · contact PI
Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugs$690,524
R01 · FY2017 · DA · contact PI
HIV Prevention and Adherence Among Priority Drug Using Populations$139,430
K02 · FY2017 · DA · contact PI
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users$600,429
R01 · FY2016 · DA · contact PI
HIV Prevention and Adherence Among Priority Drug Using Populations$139,430
K02 · FY2016 · DA · contact PI
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users$595,621
R01 · FY2015 · DA · contact PI
HIV Prevention and Adherence Among Priority Drug Using Populations$139,430
K02 · FY2015 · DA · contact PI
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users$617,274
R01 · FY2014 · DA · contact PI
HIV Prevention and Adherence Among Priority Drug Using Populations$139,430
K02 · FY2014 · DA · contact PI
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users$605,238
R01 · FY2013 · DA · contact PI
HIV Prevention and Adherence Among Priority Drug Using Populations$139,430
K02 · FY2013 · DA · contact PI
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users$689,097
R01 · FY2012 · DA · contact PI
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users$353,915
R01 · FY2010 · DA · contact PI
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users$497,164
R01 · FY2009 · DA · contact PI
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users$496,190
R01 · FY2008 · DA · contact PI
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users$490,647
R01 · FY2007 · DA · contact PI
A Healthy Transition for Newly Released HIV-Infected Prisoners$175,794
R21 · FY2007 · DA · contact PI
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users$475,258
R01 · FY2006 · DA · contact PI
A Healthy Transition for Newly Released HIV-Infected Prisoners$218,618
R21 · FY2006 · DA · contact PI
Optimizing HIV Risk Reduction for HIV Positive IDUs$182,012
K23 · FY2006 · DA · contact PI
Optimizing HIV Risk Reduction for HIV Positive IDUs$172,428
K23 · FY2005 · DA
Optimizing HIV Risk Reduction for HIV Positive IDUs$134,198
K23 · FY2004 · DA
Optimizing HIV Risk Reduction for HIV Positive IDUs$129,957
K23 · FY2003 · DA